Santhera Pharmaceuticals Holding AG: Santhera gibt den Vollzug des Umtauschangebots für die Wandelanleihe per 4. Mai 2021 bekannt
Pratteln, Schweiz, 3.
März 2021 angekündigte Umtauschangebot für die CHF
60 Millionen Wandelanleihe am 4.
Mai 2021 vollzogen wird.
Mit dem Rückkaufsinserat vom 25. März 2021 (das
Rückkaufsinserat) veröffentlichte Santhera Pharmaceuticals Holding AG ein Angebot zum Umtausch der ausstehenden CHF 60 Millionen 5%-Wandelanleihe mit Fälligkeit 2022 (die
2017/22 Wandelanleihe) nach den im Rückkaufsinserat aufgeführten Konditionen (das
Umtauschangebot). Das Umtauschangebot wurde von Anleihensgläubigern in Bezug auf die 2017/22 Wandelobligationen mit einem Gesamtnennbetrag von CHF 44 845 000 angenommen, was 74.7% der sich im Umlauf befindlichen 2017/22 Wandelanleihe entspricht.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Santhera Completes Capital Increases for Financing Arrangements
Santhera Pharmaceuticals Holding AGApril 30, 2021 GMT Pratteln, Switzerland, April 30, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,312,000 treasury shares.
On April 30, 2021, Santhera completed the ordinary capital increase resolved on March 18, 2021, by issuing 312,000 new treasury shares for purposes of the planned restructuring of the CHF 60 million convertible bond 2017-2022 (ISIN CH0353955195) and potentially for other purposes. At the same time, 2,000,000 shares were issued out of the existing authorized capital as treasury shares. The newly created registered shares will initially be held as treasury shares in order to fulfill obligations arising from Santhera’s financing instruments. After the capital increases, Santhera’s share capital amounts to 26,201,136 shares.
Santhera Pharmaceuticals Holding AG: Santhera Completes Capital Increases for Financing Arrangements
2,
shares.
On April 30, 2021, Santhera completed the ordinary capital increase resolved on March 18, 2021, by issuing 312,000 new treasury shares for purposes of the planned restructuring of the CHF 60 million convertible bond 2017-2022 (ISIN CH0353955195) and potentially for other purposes. At the same time, 2,000,000 shares were issued out of the existing authorized capital as treasury shares. The newly created registered shares will initially be held as treasury shares in order to fulfill obligations arising from Santhera s financing instruments. After the capital increases, Santhera s share capital amounts to 26,201,136 shares.
The new shares will be listed as per May 3, 2021.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Santhera Pharmaceuticals Holding AG: Santhera Reports 2020 Annual Results
4 this statement. CHF
67.7
20 as the basis for future growth
S
Pratteln, Switzerland,
Company
20
lead
uchenne muscular dystrophy (D
. Santhera started 2021 with the strong foundation of a refreshed clinical and operational strategy focused on vamorolone, which we believe can provide significant value to patients, caregivers, and ultimately shareholders. It represents the key foundation for the future of Santhera, which continues to focus on Duchenne muscular dystrophy (DMD) and other rare diseases., said
Dario Eklund, CEO of Santhera. Vamorolone is currently being developed for early stage DMD patients and recent encouraging data leads us to conclude that vamorolone could emerge as a foundational therapy in DMD for all patients irrespective of gene mutation and as a promising alternative to existing corticosteroids. Based on the collective clinical experience so far, we look forward to t